We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

375 hedge funds and large institutions have $9.25B invested in Sarepta Therapeutics in 2022 Q3 according to their latest regulatory filings, with 81 funds opening new positions, 122 increasing their positions, 114 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 36

69% more capital invested

Capital invested by funds: $5.49B → $9.25B (+$3.76B)

68% more call options, than puts

Call options by funds: $269M | Put options by funds: $160M

13% more funds holding

Funds holding: 331 → 375 (+44)

12.88% more ownership

Funds ownership: 83.85% → 96.73% (+13%)

11% more funds holding in top 10

Funds holding in top 10: 9 → 10 (+1)

7% more repeat investments, than reductions

Existing positions increased: 122 | Existing positions reduced: 114

Holders
375
Holders Change
+44
Holders Change %
+13.29%
% of All Funds
6.46%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.17%
New
81
Increased
122
Reduced
114
Closed
36
Calls
$269M
Puts
$160M
Net Calls
+$109M
Net Calls Change
+$57.4M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$577M
2
APM
Avidity Partners Management
Texas
+$95.6M
3
O
OrbiMed
New York
+$90.6M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$89M
5
Two Sigma Investments
Two Sigma Investments
New York
+$76.5M

Top Sellers

Rank Fund Capital Flow
1
Sands Capital Management
Sands Capital Management
Virginia
-$124M
2
Citadel Advisors
Citadel Advisors
Florida
-$47.5M
3
FCM
Farallon Capital Management
California
-$43.4M
4
BG
Bellevue Group
Switzerland
-$38.7M
5
State Street
State Street
Massachusetts
-$38.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PTP
251
Platform Technology Partners
New York
$338K -$35.6K -353 -10%
BFM
252
Boothbay Fund Management
New York
$338K -$13K -129 -4%
DG
253
DMC Group
Alabama
$330K +$25.1K +249 +9%
SS
254
Simplicity Solutions
Minnesota
$319K +$291K +2,890 New
AA
255
Advisory Alpha
Michigan
$318K – – –
CFG
256
Citizens Financial Group
Rhode Island
$317K -$322K -3,192 -53%
SAM
257
Sectoral Asset Management
Quebec, Canada
$310K – – –
AQR Capital Management
258
AQR Capital Management
Connecticut
$302K +$275K +2,731 New
AWM
259
Avior Wealth Management
Nebraska
$302K +$276K +2,734 New
PWM
260
Perigon Wealth Management
California
$282K -$50.4K -500 -16%
EMFAT
261
Emerald Mutual Fund Advisers Trust
Pennsylvania
$280K +$255K +2,529 New
BAM
262
Brave Asset Management
New Jersey
$276K -$118K -1,175 -32%
BC
263
Birchview Capital
Vermont
$276K +$252K +2,500 New
Stifel Financial
264
Stifel Financial
Missouri
$274K -$52.5K -521 -17%
Amundi
265
Amundi
France
$266K – – –
VCWA
266
Vanguard Capital Wealth Advisors
Colorado
$260K +$237K +2,350 New
DADC
267
D.A. Davidson & Co
Montana
$256K +$233K +2,316 New
DA
268
Duality Advisers
Florida
$254K -$949K -9,420 -80%
CIC
269
Cornercap Investment Counsel
Georgia
$247K +$226K +2,238 New
GT
270
Glenmede Trust
Pennsylvania
$243K +$223K +2,208 New
CCIA
271
Campbell & Co Investment Adviser
Maryland
$236K +$215K +2,132 New
AAM
272
Azzad Asset Management
Virginia
$235K – – –
Cambridge Investment Research Advisors
273
Cambridge Investment Research Advisors
Iowa
$233K +$213K +2,111 New
BC
274
Bridgefront Capital
Texas
$229K +$209K +2,072 New
IFPG
275
Intrepid Financial Planning Group
Indiana
$227K +$207K +2,050 New
9 10
11
12 13

SRPT Hedge Fund Activity: Q3 2022 in Review

375 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q3 2022, worth a combined $9.25B — up 69% from $5.49B a quarter earlier.

Buyers outnumbered sellers: 81 funds opened new SRPT positions and 36 closed out — a net gain of 45 holders — while 122 added to existing stakes and 114 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $577M. The largest seller was Sands Capital Management, cutting an estimated $124M.

  • 375 institutional investors held Sarepta Therapeutics (SRPT) as of Q3 2022, up from 331 in Q2 2022.
  • Funds reported $9.25B of Sarepta Therapeutics stock for Q3 2022, up 69% quarter-over-quarter.
  • 81 funds opened new Sarepta Therapeutics positions in Q3 2022 and 36 closed out, a net change of +45 holders.
  • The largest Sarepta Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $577M added.
  • The largest Sarepta Therapeutics seller in Q3 2022 was Sands Capital Management, an estimated $124M sold.

Based on aggregated 13F filings for Q3 2022.